Insulet Corporation $PODD Shares Acquired by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. increased its stake in Insulet Corporation by 5.8%, holding approximately 79,821 shares valued at $25 million as of its latest SEC filing.
• Insulet reported better-than-expected earnings of $1.17 EPS for the last quarter, surpassing analysts' expectations and demonstrating substantial year-over-year revenue growth of 32.9%.
• Several brokerages have raised their price targets for Insulet, with a consensus average target of $343.06 and a majority of analysts rating the stock as a "Buy".

Congress Asset Management Co. grew its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 5.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 79,821 shares of the medical instruments supplier's stock after purchasing an additional 4,382 shares during the quarter. Congress Asset Management Co. owned approximately 0.11% of Insulet worth $25,078,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Zions Bancorporation National Association UT bought a new stake in shares of Insulet during the 1st quarter valued at about $26,000. Larson Financial Group LLC grew its position in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 81 shares during the last quarter. SouthState Corp grew its position in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. bought a new stake in shares of Insulet during the 2nd quarter valued at about $32,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Insulet during the 1st quarter valued at about $53,000.

Insulet Price Performance

NASDAQ PODD opened at $318.00 on Friday. Insulet Corporation has a 52 week low of $225.37 and a 52 week high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $22.38 billion, a price-to-earnings ratio of 96.66, a price-to-earnings-growth ratio of 2.69 and a beta of 1.36. The company has a 50-day moving average price of $319.01 and a two-hundred day moving average price of $296.63.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business's revenue was up 32.9% on a year-over-year basis. During the same period last year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PODD. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Piper Sandler boosted their price objective on shares of Insulet from $320.00 to $360.00 and gave the company an "overweight" rating in a research report on Tuesday, September 16th. Oppenheimer boosted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $343.06.

Insider Activity at Insulet

In other news, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.